Genetic Determinants of Radiotherapy Resistance in Uveal Melanoma
Journal of Cancer Biomoleculars and Therapeutics · 09.07.2026 · 3 (3) · 1-16
DOI: 10.62382/jcbt.v3i3.108 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cancer Biomoleculars and Therapeutics, online erschienen am 09.07.2026. Verfasst von Hamed Charkhian und 6 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Radiotherapy remains the cornerstone of local treatment for uveal melanoma (UM), achieving high rates of primary tumor control. Nevertheless, a substantial proportion of patients experience disease progression and metastatic relapse, underscoring a fundamental biological limitation of radiotherapy efficacy in this malignancy. Accumulating evidence indicates that radioresistance in UM is not driven by high mutational burden, but rather by a distinctive genetic architecture dominated by chromosomal alterations and adaptive DNA damage response programs. High-risk cytogenetic states in UM, particularly those defined by large-scale chromosomal imbalance, have emerged as key biological contexts shaping radiotherapy tolerance. Rather than acting as passive prognostic markers, these configurations appear to remodel genome maintenance capacity by selectively dampening tumor-suppressive safeguards while favoring DNA damage tolerance and survival-oriented repair responses. In parallel, early oncogenic events that drive tumor initiation indirectly reinforce radioresistance by sustaining pro-survival signaling programs, transcriptional adaptability, and stress resilience. Together, these features establish a cellular state in which radiation-induced damage is accommodated rather than eliminated, permitting clonogenic persistence despite adequate local dose delivery. This review integrates genomic, cytogenetic, and radiobiological evidence to propose a unifying framework in which UM radioresistance arises from coordinated genetic reprogramming of DNA repair and survival pathways. Understanding these determinants is essential for the rational development of radiosensitization strategies and for improving long-term disease control in UM.
Zitieren
APA
Charkhian, H., Dehaghani, M. H. M., Negin, S. N. S., Simaei, Z., Pourteimoor, V., Bahararjmand, Z., & Tuncer, S. B. (2026). Genetic Determinants of Radiotherapy Resistance in Uveal Melanoma. Journal of Cancer Biomoleculars and Therapeutics, 3(3), 1-16. https://doi.org/10.62382/jcbt.v3i3.108
Vancouver
Charkhian H, Dehaghani MHM, Negin SNS, Simaei Z, Pourteimoor V, Bahararjmand Z, et al. Genetic Determinants of Radiotherapy Resistance in Uveal Melanoma. Journal of Cancer Biomoleculars and Therapeutics. 2026;3(3):1-16. doi:10.62382/jcbt.v3i3.108
BibTeX
@article{Charkhian2026,
author = {Charkhian, Hamed and Dehaghani, Motahareh Haji Mohammadi and Negin, Seyedeh Negin Seyedeh and Simaei, Zahra and Pourteimoor, Vida and Bahararjmand, Zahra and Tuncer, Seref Bugra},
title = {Genetic Determinants of Radiotherapy Resistance in Uveal Melanoma},
journal = {Journal of Cancer Biomoleculars and Therapeutics},
year = {2026},
volume = {3},
number = {3},
pages = {1--16},
doi = {10.62382/jcbt.v3i3.108}
}
EUVIMED